Showing results (1-10 of 6,842) with videos related to

Sort By:
Pageof 685
Medical Decision Making : an International Journal of the Society for Medical Decision Making|December 1, 2025
When Do Published Cost-Effectiveness Analyses Include Societal Costs? An Empirical Analysis, 2013-2023Divya Patil, Bengt Liljas, Peter J Neumann, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|March 4, 2009
On the welfare theoretic foundation of cost-effectiveness analysis-the case when survival is not affectedBengt Liljas
Health Economics|December 16, 2010
Welfare, QALYs, and costs - a commentBengt Liljas
Health Economics|September 6, 2007
On future non-medical costs in economic evaluationsBengt Liljas, Göran S Karlsson, Nils-Olov Stålhammar
Cancer Management and Research|December 14, 2022
Considerations for the Utility of Real-World Evidence Beyond Trial Data in Advanced NSCLC: The Case of Frontline Tyrosine Kinase InhibitorsPriyanka Gaitonde, Viktor Chirikov, Sneha Kelkar, et al.
Advances in Therapy|June 12, 2004
Once-daily budesonide inhalation powder (Pulmicort Turbuhaler) improves health-related quality of life in adults previously receiving inhaled corticosteroidsFrank C Hampel, Mark Sugar, Bhash Parasuraman, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|March 29, 2023
Cost-effectiveness of acalabrutinib regimens in treatment-naïve chronic lymphocytic leukemia in the United StatesTalha Munir, Victoria Genovez, Victor Genestier, et al.
Journal of Market Access & Health Policy|April 24, 2026
Mapping the Use of Real-World Evidence Across the EU Health Technology Assessment Regulation: Methodological Considerations, Challenges, and Opportunities for HarmonizationGrammati Sarri, Bengt Liljas, Keith R Abrams, et al.
Clinical Therapeutics|March 5, 2004
Effectiveness of budesonide administered via dry-powder inhaler versus triamcinolone acetonide administered via pressurized metered-dose inhaler for adults with persistent asthma in managed care settingsKevin B Weiss, Bengt Liljas, William Schoenwetter, et al.
Clinical Drug Investigation|February 17, 2010
The burden of disrupting gastro-oesophageal reflux disease: a database study in US and European cohortsSamira Toghanian, Peter Wahlqvist, David A Johnson, et al.
Pageof 685